The Phase 3 trial (NCT06588296) investigating ixekizumab concomitantly administered with tirzepatide in adults with psoriatic arthritis and obesity or overweight reached its primary completion on 2025-11-18. This study aims to demonstrate improved psoriatic arthritis outcomes and weight reduction with the combination therapy compared to ixekizumab alone.
Background
The trial's main purpose is to evaluate the efficacy of ixekizumab and tirzepatide administered concomitantly. It seeks to show that this combination can lead to improvement in psoriatic arthritis and achieve weight reduction in participants with psoriatic arthritis and obesity or overweight, especially those with at least one weight-related comorbid condition, compared to receiving ixekizumab alone.
Trial design
The study, identified as NCT06588296, is a Phase 3 trial. It enrolled 279 participants diagnosed with psoriatic arthritis and obesity or overweight. The trial investigates the concomitant administration of ixekizumab and tirzepatide. The study design aims to compare the outcomes of the combination therapy against treatment with ixekizumab alone.
What this means
The primary completion of this Phase 3 trial signifies that data collection for the study's primary objectives has concluded. The trial's findings, once released, are expected to provide insights into the potential benefits of combining ixekizumab and tirzepatide for managing both psoriatic arthritis and obesity in affected individuals. This could offer a new therapeutic approach for patients with these co-occurring conditions.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT06588296, titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight," was updated with the primary completion date of 2025-11-18 on clinicaltrials.gov.